Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections
- PMID: 17353238
- PMCID: PMC1891381
- DOI: 10.1128/AAC.01084-06
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections
Abstract
Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A prospective method was developed to create homogeneous patient populations for PK-PD analyses. Evaluable patients from three clinical trials were pooled for analysis. Patients received a tigecycline 100-mg loading dose/50 mg every 12 h or a 50-mg loading dose/25 mg every 12 h. At the test-of-cure visit, microbiologic and clinical responses were evaluated. Patients were prospectively evaluated and classified into cohorts based on baseline pathogens: S. aureus only (cohort 1), monomicrobial S. aureus or streptococci (cohort 2), two gram-positive pathogens (cohort 3), polymicrobial (cohort 4), or other monomicrobial infections (cohort 5). A prospective procedure for combining cohorts was used to increase the sample size. Logistic regression evaluated steady-state 24-h area under the concentration-time curve (AUC(24))/MIC ratio as a predictor of response, and classification and regression tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with pooled cohorts 2 and 3, the focus of these analyses, and included 35 patients with 40 S. aureus and/or streptococcal pathogens. CART analyses identified a significant AUC/MIC breakpoint of 17.9 (P = 0.0001 for microbiological response and P = 0.0376 for clinical response). The continuous AUC/MIC ratio was predictive of microbiological response based on sample size (P = 0.0563). Analysis of all pathogens combined decreased the ability to detect exposure-response relationships. The prospective approach of creating homogeneous populations based on S. aureus and streptococci pathogens was critical for identifying exposure-response relationships.
Figures

Similar articles
-
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. doi: 10.1128/AAC.00813-07. Epub 2007 Oct 22. Antimicrob Agents Chemother. 2008. PMID: 17954694 Free PMC article. Clinical Trial.
-
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.Diagn Microbiol Infect Dis. 2009 Feb;63(2):155-9. doi: 10.1016/j.diagmicrobio.2008.10.011. Diagn Microbiol Infect Dis. 2009. PMID: 19150707
-
Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014. Diagn Microbiol Infect Dis. 2009. PMID: 19073300
-
Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.Int J Infect Dis. 2007 May;11 Suppl 1:S7-15. doi: 10.1016/S1201-9712(07)60002-2. Int J Infect Dis. 2007. PMID: 17603950 Review.
-
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71. doi: 10.1016/j.diagmicrobio.2005.05.006. Diagn Microbiol Infect Dis. 2005. PMID: 16105560 Review.
Cited by
-
Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Clin Pharmacokinet. 2013 Jul;52(7):511-42. doi: 10.1007/s40262-013-0062-9. Clin Pharmacokinet. 2013. PMID: 23605634 Review.
-
Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3. doi: 10.1128/AAC.00922-07. Epub 2008 Jun 2. Antimicrob Agents Chemother. 2008. PMID: 18519719 Free PMC article.
-
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.Antimicrob Agents Chemother. 2012 Mar;56(3):1466-70. doi: 10.1128/AAC.01743-10. Epub 2011 Dec 12. Antimicrob Agents Chemother. 2012. PMID: 22155834 Free PMC article. Clinical Trial.
-
Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Ther Clin Risk Manag. 2007 Dec;3(6):1059-70. Ther Clin Risk Manag. 2007. PMID: 18516315 Free PMC article.
-
In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02368-16. doi: 10.1128/AAC.02368-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28193651 Free PMC article.
References
-
- Babinchak, T., E. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl.):S354-S367. - PubMed
-
- Christianson, J., D. Andes, and W. Craig. 2001. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1103.
-
- Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10. - PubMed
-
- Doern, G. V., R. N. Jones, M. A. Pfaller, K. C. Kugler, and M. L. Beach. 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. 34:65-72. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical